ADR120S, Inc.【JP:3750】Stock Price

Saitori Cell Research Institute is a corporate group that invests in medical assets, buys and sells real estate, invests in real estate development projects, and manages owned properties. The group operates through seven consolidated subsidiaries.

In the Medical Business segment, subsidiaries including Saitori Therapeutics Inc. and Saitori Cell Therapy Inc. invest in medical assets. Saitori Therapeutics sells Cellution centrifuges and cell therapy kits to medical institutions, providing regenerative cell-based treatments.

Saitori Cell Research Institute has obtained approval for the Cellution Cell Therapy Kit as a medical device for treating male stress urinary incontinence. The company is currently pursuing insurance coverage procedures with the goal of providing treatment under insurance-covered medical care.

The Real Asset Business segment comprises the real estate division, which consists of Dewey Inc. and Satellite Nagoya Inc. These entities engage in holding and leasing high-yield properties, investing in development projects, and providing real estate brokerage services. However, Satellite Nagoya has ended its operations of off-track betting facilities for public racing.

Saitori Cell Research Institute qualifies as a specified listed company and applies materiality thresholds for insider trading regulations based on consolidated financial figures. This approach ensures transparent management.

Cytori Cell Research Institute is advancing its growth strategy centered on cell therapy services. The company aims to enhance corporate value through strengthened corporate governance and is proceeding with the sale of owned real estate to build a business structure resilient to economic fluctuations.

The company's management strategy focuses on shifting from real asset operations to medical operations. Specifically, it has established three pillars: research and development in cell therapy, service provision under both private and insurance-covered medical care, and international expansion.

Through its medical asset operations, Cytori Cell Research Institute is working to address intractable diseases, dementia, and lifestyle-related diseases. In particular, the company is actively pursuing market entry into overseas markets, including Saudi Arabia.

In addition to manufacturing, importing, exporting, and selling medical devices, the company aims to enhance corporate value by accelerating research and development in cell therapy and deploying differentiated, competitive services.

As management targets, the company has set goals for increased sales, operating profit, and ROE, with a basic policy of maintaining stable dividends. Regarding the dividend for the fiscal year ending March 2025, the company has decided on no dividend distribution, taking into account business performance and financial condition.